A multicenter, randomized, open label clinical trial for safety evaluation of an allergen immunotherapy with an accelerated dose escalation schedule using one strength of an aluminium hydroxide adsorbed allergoid preparation of birch pollen allergens in adult and pediatric patients with moderate to severe seasonal allergic rhinitis or rhinoconjunctivitis with or without bronchial asthma
Latest Information Update: 12 Sep 2023
At a glance
- Drugs Birch pollen allergy immunotherapy (Primary)
- Indications Allergic rhinitis; Rhinoconjunctivitis; Seasonal allergic rhinitis
- Focus Adverse reactions
- Acronyms ONSeT Birch
- Sponsors Allergopharma
- 21 Jun 2023 Status changed from recruiting to completed.
- 16 Jun 2023 This trial has been completed in Poland (Date of the global end of the trial: 29 Mar 2023).
- 01 Jan 2022 Planned End Date changed to 20 Jul 2023.